Advertisement

Topics

Rucaparib significantly improved PFS of ovarian cancer patients in phase III ARIEL maintenance trial

06:33 EDT 20 Jun 2017 | ecancermedicalscience

Data from the confirmatory phase 3 ARIEL3 trial of has been announced, in which rucaparib successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. ARIEL3 is...

Original Article: Rucaparib significantly improved PFS of ovarian cancer patients in phase III ARIEL maintenance trial

NEXT ARTICLE

More From BioPortfolio on "Rucaparib significantly improved PFS of ovarian cancer patients in phase III ARIEL maintenance trial"

Advertisement
Quick Search
Advertisement
Advertisement